# A Prospective, Exploratory Study of Becotatug Vedotin Plus Putlimab for Neoadjuvant Therapy and Adjuvant Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

> **NCT07707167** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu Cancer Institute & Hospital** · enrollment: 35 (estimated)

## Conditions studied

- LA HNSCC

## Interventions

- **DRUG:** Pucotenlimab
- **DRUG:** Becotatug vedotin
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT07707167
- **Lead sponsor:** Jiangsu Cancer Institute & Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2028-01-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07707167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07707167, "A Prospective, Exploratory Study of Becotatug Vedotin Plus Putlimab for Neoadjuvant Therapy and Adjuvant Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07707167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*